Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The APRIL codon 67 was significantly associated with SLE risk under the dominant model adjusted by ethnicity (odds ratio, 95% confidence interval and P-values were 1.45 and 1.02-2.06 and 0.036, respectively).
|
17569747 |
2007 |
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A single-nucleotide polymorphism (SNP) for rs11552708 of APRIL gene was analyzed by real-time PCR in 60 SLE Iranian children and 64 healthy controls.
|
27878683 |
2017 |
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We previously reported the association of APRIL haplotypes formed by two nonsynonymous polymorphisms, Gly67Arg and Asn96Ser, with systemic lupus erythematosus.
|
21984075 |
2012 |
Lupus Erythematosus, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus.
|
12730512 |
2003 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The present amplification via primer ligation at the mutation (APRIL-ATM) has potential applications in the detection of mutagen-generated genetic alterations, early detection of tumor marker mutations in bodily discharges and the diagnosis of minimal residual disease.
|
12202623 |
2002 |
Reticulocyte count (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
Adenocarcinoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Other changes were specific for adenomas (PPA1 and PPA2 up-regulation; KCTD12 downregulation) or adenocarcinoma (ANP32B, G6PD, RCN1, and SET up-regulation; downregulated AKR1B1, APEX1, and PPA1).
|
28062797 |
2017 |
Neoplasm, Residual
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The present amplification via primer ligation at the mutation (APRIL-ATM) has potential applications in the detection of mutagen-generated genetic alterations, early detection of tumor marker mutations in bodily discharges and the diagnosis of minimal residual disease.
|
12202623 |
2002 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL.
|
29783918 |
2018 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.
|
27390168 |
2017 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our results have identified and confirmed APRIL as a new target involved in B-cell activation, in the maintenance of plasma cell survival and subsequent increased autoantibody production that sustains lupus development in mice.
|
28267197 |
2017 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
|
30467093 |
2019 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
These include the BAFF/APRIL dual inhibitor, atacicept, and the BAFF inhibitor, belimumab, which is approved as an add-on therapy for patients with active SLE.
|
28215100 |
2017 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protective effect of APRIL c.199A/A homozygotes in SLE was replicated (odds ratio 0.50, 95% confidence interval 0.30-0.83, P = 0.0073; pooled P = 0.0001, Pcorr = 0.007).
|
17307753 |
2007 |
Lupus Erythematosus, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
BLyS and APRIL are cytokines from the tumor necrosis factor family which play an important role in systemic lupus erythematosus (SLE).
|
23171638 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth-promoting as well as apoptosis-inducing effects of APRIL have been described.
|
11550092 |
2001 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
APRIL was observed near Ki67(+) nuclei and was distributed heterogeneously in the cancer cells, in the leukocyte infiltrate, and in the myoepithelial layer adjacent to the tumor area; these results imply that APRIL provides proliferation signals to tumor cells through paracrine and autocrine signaling.
|
25750171 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, our results showed that chemokine-mediated recruitment of neutrophils secreting the tumor-promoting factor APRIL mediates DLBCL progression.<i></i>.
|
27923834 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It was shown that NFkB activation in MM tumors results mainly from extrinsic signaling by APRIL and BAFF ligands that stimulate receptors on normal plasma cells as well as on pre-malignant monoclonal gammopathy of undetermined significance (MGUS) and MM tumors.
|
20890394 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, APRIL-transfected NIH-3T3 cells show an increased rate of tumor growth in nude mice compared with the parental cell line.
|
9743536 |
1998 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia (B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may provide a therapeutic strategy to treat B-CLL patients.
|
15488762 |
2004 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
APRIL can stimulate tumor cell growth and is up-expressed in cancer tissues, especially in CRC (colorectal cancer).
|
24771268 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, whereas interaction of APRIL with HSPG does not influence APRIL-induced proliferation of T cells, it is crucial for its tumor growth-promoting activities.
|
15846369 |
2005 |